医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GI Dynamics Announces Results of Special Meeting

2018年11月06日 AM12:32
このエントリーをはてなブックマークに追加


 

BOSTON & SYDNEY

GI Dynamics, Inc. (ASX:GID), a medical device company that is developing EndoBarrier, held a Special Meeting on Monday, 29 October 2018 at 5:00pm United States Eastern Daylight Time (being Tuesday, 30 October 2018 at 8:00am Australian Eastern Daylight Time) and is pleased to announce that each of the resolutions put to stockholders as set forth in the Proxy Statement dated 15 October 2018 (Proxy Statement), were passed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181105005633/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

The information required under section 251AA of the Corporations Act is attached.

As specified in the Proxy Statement, the Company notes that the CDIs to be issued to Crystal Amber Fund Limited (or its nominee) and certain sophisticated and professional investors in Australia and the United States under the second tranche of the Placement will be issued after receipt of all second tranche funds and will rank equally in all respects with CDIs on issue at the date of allotment.

About GI Dynamics

GI Dynamics Inc. (ASX: GID) is the developer of EndoBarrier, an endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale and is limited by federal law to investigative use only. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit gidynamics.com.

Forward-Looking Statements

The announcement may contain forward-looking statements. These statements are based on GI Dynamics management’s current estimates and expectations of future events as of the date of this announcement. Furthermore, the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements.

These risks and uncertainties include, but are not limited to, risks associated with our ability to continue to operate as a going concern; our ability to raise sufficient additional funds to continue operations and to conduct the planned clinical trial of EndoBarrier in the United States (GID 18-1 Trial); our ability to execute the GID 18-1 Trial under FDA IDE; our ability to enlist clinical trial sites and enroll patients in accordance with the GID 18-1 Trial; the risk that the FDA stops the GID 18-1 Trial early as a result of the occurrence of certain safety events or does not approve an expansion of the GID 18-1 Trial; our ability to maintain compliance with our obligations under our existing convertible note and warrant agreements executed with Crystal Amber Fund Limited, including our obligations to make payment on the relevant notes that are due in December 2018; obtaining and maintaining regulatory approvals required to market and sell our products; the possibility that future clinical trials will not be successful or confirm earlier results; the timing and costs of clinical trials; the timing of regulatory submissions; the timing, receipt and maintenance of regulatory approvals; the timing and amount of other expenses; the timing and extent of third-party reimbursement; intellectual-property risk; risks related to excess inventory; risks related to assumptions regarding the size of the available market; the benefits of our products; product pricing; timing of product launches; future financial results; and other factors, including those described in our filings with the U.S. Securities and Exchange Commission.

Given these uncertainties, one should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless we are required to do so by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005633/en/

CONTACT

Investor Relations
United States:
GI Dynamics, Inc.
Janell
Shields, +1 (781) 357-3280
investor@gidynamics.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • GI Dynamics Announces Close of Second Tranche of Placement and Grant of Options to CEO
  • 瑞思迈完成对MatrixCare的收购
  • レスメドがマトリックスケアの買収を完了
  • SpinalCyte宣布,注射CybroCell™后,MRI转归可维持12个月
  • コックスバザールの病院で14万人のロヒンギャ難民に24時間体制の医療援助を提供